Dr. Bhasin is Co-Director of Genomics, Proteomics, Bioinformatics and Systems Biology Center at Beth Israel Deaconess Medical Center (BIDMC), which provide core assistance to medical center investigators in the use of various proteomics, genomics and bioinformatics technologies. Dr. Bhasin is experienced Bioinformatician/biostatistician with strong track record in computational vaccine design, functional proteomics, systems biology and transcriptional data analysis. He has been applying systematic and comprehensive statistical and Bioinformatics strategies for analysis of transcriptome and proteomics data to define disease mechanisms at a molecular level and to identify novel prognostic and predictive cancer biomarkers.
Development of molecular diagnostics platforms for cancer diagnosis and prognosis.
Molecular diagnostics is a rapidly growing area for diagnosis, prognosis and treatment of diseases on the basis of molecular alterations. The profiling of molecular alterations not only helps in stratifying diseases but also helps in providing and choosing a targeted therapy on the basis of disease driving molecular alterations. Our lab is actively involved developing biomarkers for diagnosis, prognosis and treatment of various cancers by identifying molecular markers on the basis of multi-dimensional diagnosis of omics data using systems biology approaches. We have developed a platform for comprehensive precision medicine by isolating the cancer driving mutations by performing integrated analysis of genetics, epigenomics and transcriptome data .
Identification of biomarkers for early detection of pancreatic, Kidney and Colons cancers, as well as glioblastoma
Our lab is invoved in development of novel biomarkers early detection, outcome prediction, risk assessment, companion diagnostic, patient stratification and treatment of different cancers by developing novel methods for meta-analysis of omics data and predictor development. We have a novel therapeutic targets and biomarkers for early detection, and treatment of Pancreatic Adenocarcinoma on the basis of expression profile of genes and miRNA by using innovative approach for data integration. The overview of Pancreatic cancer biomarker is shown below and spinned out as startup “Biomarx therapeutics” for further validation. Similar Biomarkers are also developed for Renal , Colon and Glioblastoma which are undergoing validation to determine their performance.